



SPENCER J. COX  
*Governor*

DEIDRE M. HENDERSON  
*Lieutenant Governor*

# UTAH DEPARTMENT OF COMMERCE

## Division of Professional Licensing

MARGARET W. BUSSE  
*Executive Director*

MARK B. STEINAGEL  
*Division Director*

To all Controlled Substance Providers & Pharmacies:

We hope you are aware and have already been informed of the changes last month regarding the elimination of the "DATA-Waiver Program". The letter you should have received from the DEA is included here. We are most interested in making sure all the users of the Controlled Substance Database (CSD) are informed, and understand that there will be no issues with using the CSD.

As the DEA has determined that X-DEA numbers will no longer be used, the CSD has the ability to continue to receive X-DEA numbers while pharmacies and their vendors make the necessary software changes. The CSD feels that a phasing out approach will allow the least disruption to receiving data from pharmacies. The CSD will continue to accept X-DEA numbers while the new law affects pharmacy reporting.

The new law has a training requirement that goes into effect June 21, 2023. SAMHSA's notification stated: "all persons who obtain or renew a controlled substances license from the DEA will be required to receive eight hours of training on SUD, with certain exceptions." Once there is clarification on this requirement, we will reach out again to let you all know any details we become aware of. The good news is that this training will count towards the credits you need in Utah for a controlled substance license and will cover 4 years of the credit requirements.

Sincerely,

Mark Steinagel  
Director, Division of Professional Licensing

### Letter from DEA:

Dear Registrants:

On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the "DATA-Waiver Program."

DEA fully supports this significant policy reform. In this moment, when the United States is suffering tens of thousands of opioid-related drug poisoning deaths every year, the DEA's top priority is doing everything in our power to save lives. Medication for opioid use disorder helps those who are fighting to overcome opioid use disorder by sustaining recovery and preventing overdoses. At DEA, our goal is simple: we want medication for opioid use disorder to be readily and safely available to anyone in the country who needs it. The elimination of the X-Waiver will increase access to buprenorphine for those in need.

All DEA registrants should be aware of the following:

- A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
- Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
- There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
- The Act does not impact existing state laws or regulations that may be applicable.

Separately, the Act also introduced new training requirements for all prescribers. These requirements will not go into effect until June 21, 2023. The DEA and SAMHSA are actively working to provide further guidance and DEA will follow up with additional information on these requirements shortly. Importantly, these new requirements do not impact the changes related to elimination of the DATA-Waiver Program described above.